التفاصيل البيبلوغرافية
| العنوان: |
New Cancer Study Findings Recently Were Reported by Researchers at University of Hawaii Manoa (Pan-cancer Analyses of Bromodomain Containing 9 As a Novel Therapeutic Target Reveals Its Diagnostic, Prognostic Potential and Biological Mechanism...). |
| المصدر: |
Immunotherapy Weekly; 2024, p776-776, 1p |
| مصطلحات موضوعية: |
RESEARCH personnel, THERAPEUTICS, WNT/BETA-catenin pathway, PROGRAMMED death-ligand 1, GENETICS |
| مستخلص: |
A recent report from the University of Hawaii Manoa highlights the potential of the protein coding gene Bromodomain containing 9 (BRD9) as a therapeutic target for various types of cancer. The study conducted pan-cancer analyses of BRD9 expression and found that it exhibited elevated expression in a wide range of tumors. The research also revealed that BRD9 could serve as a novel biomarker for diagnosing different cancer types and accurately forecasting the prognosis of melanoma patients receiving anti-programmed cell death 1 immunotherapy. Additionally, the study identified the BRD9/SMARCD1 axis as a potential prognostic factor for liver hepatocellular carcinoma and mesothelioma. Experimental validation in lung and colon cancer patients showed that knocking down BRD9 inhibited cancer development. Overall, this research sheds light on the diagnostic, prognostic, and therapeutic potential of BRD9 in human tumors. [Extracted from the article] |
|
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
